Miguel Martín, Elgene Lim, Mariana Chavez-MacGregor, Aditya Bardia, Jiong Wu, Qingyuan Zhang, Zbigniew Nowecki, Felipe Melo Cruz, Rustem Safin, Sung-Bae Kim, Christian Schem, Alberto J Montero, Sarah Khan, Reeti Bandyopadhyay, Heather M Moore, Mahesh Shivhare, Monika Patre, Jorge Martinalbo, Laura Roncoroni, Pablo Diego Pérez-Moreno, Joohyuk Sohn
PURPOSE: To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor-positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455). METHODS: Post-/pre-/perimenopausal women, or men, age 18 years or older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines of systemic therapy (≤1 targeted, ≤1 chemotherapy regimen, prior fulvestrant allowed) were randomly assigned 1:1 to giredestrant (30 mg oral once daily) or fulvestrant/aromatase inhibitor per local guidelines (+luteinizing hormone-releasing hormone agonist in pre-/perimenopausal women, and men) until disease progression/unacceptable toxicity...
March 27, 2024: Journal of Clinical Oncology